Browse the evidence

Regular consumption of non-nutritive sweeteners (NNS) does not have conclusive evidence for beneficial or harmful effects on major health outcomes including appetite, short-term food intake, cancer risk, diabetes risk, dental caries, weight gain, or obesity in healthy subjects.

Current scientific evidence does not support the idea that non-nutritive sweeteners (like aspartame, sucralose, or stevia) are inherently harmful or beneficial for weight, cancer, or diabetes risk in healthy people. While some studies show mixed results on appetite, the overall body of research does not confirm significant health benefits or harms. You can use them as part of a balanced diet without expecting specific health outcomes based on current data.

Weight loss interventions in overweight and obese men do not show consistent or significant improvements in fertility outcomes due to a lack of high-quality randomized studies.

For overweight or obese men seeking to improve fertility, current evidence is insufficient to recommend specific weight loss protocols, though general health benefits apply. More research is needed.

Omega-3 fatty acid supplementation (specifically DHA) shows promise in preclinical models for reducing beta-amyloid and oxidative stress, but current clinical evidence is insufficient to recommend it for the general prevention or treatment of cognitive frailty or dementia.

Focus on obtaining Omega-3 fatty acids through dietary sources like fish rather than supplements for general cognitive health. Do not use Omega-3 supplements as a primary treatment or prevention strategy for dementia, as current clinical evidence is insufficient to support this use, unless you have a specific deficiency.

Exercise induces a phenotypic switch in white adipose tissue (WAT) to thermogenic 'beige' adipocytes via multiple mechanisms including myokine secretion (irisin, IL-6, meteorin-like), natriuretic peptides, and angiogenesis, although the metabolic benefit and necessity of this process in humans remain uncertain.

Exercise likely triggers biological changes in fat tissue (browning) in animals, but this hasn't been proven to happen or help in humans. Don't rely on 'browning' as a weight loss strategy; focus on the proven benefits of exercise like improved insulin sensitivity and cardiovascular health.

Intermittent Fasting (IF) in normal-weight subjects may cause adverse metabolic effects, including increased visceral fat, muscle insulin resistance, and increased intramyocellular triglycerides, which are not seen with Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER).

If you are already lean, avoid total fasting (0 calories). It may cause your body to store fat in your muscles and liver, worsening insulin sensitivity. Stick to partial restriction (eating some food) if you want to try intermittent fasting.

Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.

Research suggests asprosin might increase hunger and liver glucose output, but studies are inconsistent. Some early positive findings may have been due to experimental errors. Until the science is settled, focus on proven methods for managing hunger and blood sugar like balanced nutrition and exercise.

Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.

Current research indicates asprosin might protect heart cells from damage in diabetic conditions and improve stem cell therapy outcomes for heart attacks. However, this is still in early research stages. For now, managing cardiovascular risk factors remains the standard of care.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

Illicit use of AAS by competitive athletes is contrary to the rules and ethics of many sport governing bodies.

Athletes should be aware of the ethical implications and potential consequences of AAS use.

High-quality studies are needed to provide definitive answers regarding the safety and duration of preoperative drug cessation for GLP-1-RAs.

Clinicians should advocate for more research to establish clear guidelines for GLP-1-RAs in the perioperative context.

There are numerous research opportunities to explore the use of metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention.

Researchers should focus on investigating the cancer prevention potential of obesity treatments.

Long-term data on the efficacy and safety of Tirzepatide are still forthcoming.

Practitioners should remain cautious and await further data on long-term outcomes before fully endorsing TZP.

Pharmacovigilance is vital in real-world settings due to the absence of sufficiently long-term studies.

Clinicians should remain vigilant about the long-term effects of AOMs in practice.

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

BMI categories are arbitrary classifications that do not accurately reflect health risks or body fat levels, and using them as a proxy for disease leads to misdiagnosis and stigma.

Do not rely on BMI alone to determine your health. It is an arbitrary cutoff that fails to account for muscle mass or individual health markers. Focus on how you feel, your fitness, and metabolic health markers rather than a number on a scale.

Bariatric surgery (RYGB, sleeve gastrectomy) does not result in clinically significant improvements in semen volume, sperm concentration, morphology, or DNA damage in men with obesity.

Do not expect bariatric surgery to improve your fertility. While it helps with weight, studies show it does not significantly improve sperm quality or DNA integrity. If fertility is a priority, lifestyle changes are a more reliable first step.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.